Mutation detail:
| Mutation site | Y248del |
| Virus | SARS-CoV-2 |
Mutation level  |
Amino acid level |
| Gene/protein/region type | S |
| Gene ID | 43740568 |
| Country | Peru |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | - |
| Sample |
Human |
| Variants | - |
| Viral reference sequence | NC_045512.2 |
| Drug/antibody/vaccine | - |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Spike glycoprotein |
| Uniprot protein ID | P0DTC2 |
| Protein length | 1273 amino acids |
| Protein description | Spike protein is one of the structural proteins of SARS-CoV-2. The monomeric protein consists of one large ectodomain, a single-pass transmembrane anchor, and a short intracellular tail at C-terminus. It encompasses 22 glycosylation sites. S protein cleaves into two subunits namely S1 and S2 following receptor recognition. Receptor Binding Domain (RBD) in S1 subunit plays a major role in ACE2 receptor binding. |
Literature information:
| Pubmed ID | 34704780 |
| Clinical information | No |
| Disease | - |
| Published year | 2021 |
| Journal | Microbiology spectrum |
| Title | The Emergence of Sars-CoV-2 Variant Lambda (C.37) in South America |
| Author | Pedro E Romero, Alejandra Davila-Barclay, Guillermo Salvatierra, Luis Gonzalez, Diego Cuicapuza |
| Evidence | C.37 contains a novel deletion (S: del 246 to 252, located at the N-terminal domain) plus seven nonsynonymous mutations in the Spike gene (G75V, T76I, D253N, L452Q, F490S, D614G, T859N) (Fig. 1C). Mutations L452Q and F490S both map to the Spike proteins receptor-binding domain (RBD). While L452Q is almost exclusive to C.37, L452R is present in variant of concern (VOC) delta (B.1.617.2) and variants of interest (VOI) epsilon (B.1.427/B.1.429) and kappa (B.1.617.1) and is associated with increased affinity for the ACE2 receptor (2). F490S has been associated with reduced in vitro susceptibility to antibody neutralization (3, 4). C.37 also displays the ORF1a del 3675 to 3677 deletion, found in VOCs alpha, beta, and gamma (5). |